If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 51 - 60 of 281
A Phase 2, Randomized, Open-Label Three-Arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants w
Lenvatinib with or without Pembrolizumab And SOC For R/M HNSCC After Platinum And Immunotherapy
Protocol No
MERCK-MK-7902-009
Categories
Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Protocol No
HJKC3-0002
Categories
Phase II Study Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma (PRORADGLIO Study)
This project is being done to to assess the efficacy of substituting Pulsed Reduced Dose
Radiotherapy (pRDR) for standard radiation therapy in the treatment of Glioblastoma
(GBM).
Radiotherapy (pRDR) for standard radiation therapy in the treatment of Glioblastoma
(GBM).
Protocol No
IIT-STRAZA-PRORADGLIO
Categories
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS SAmples Study
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples (PANCREAS)
Protocol No
IIT-TSAI-PANCREAS-TRIAL
Categories
Treatment Free Remission After Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Treatment Free Remission After Asciminib plus Imatinib in CP-CML
Protocol No
HJKC3-0003
Categories
Optimizing Neurocognition with Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole Brain Radiation Therapy for Brain Metastases
This project is being done to test a new technique called pulsed reduced dose-rate
(PRDR) whole brain radiation therapy in combination with the drug Memantine to reduce the
neurocognitive effects of treating brain metastases.
(PRDR) whole brain radiation therapy in combination with the drug Memantine to reduce the
neurocognitive effects of treating brain metastases.
Protocol No
IIT-SAEED-ONCO-RT
Categories
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Patients with Previously Treated BTK Naïve Mantle Cell Lymphoma
Protocol No
LOXO-BTK-20019
Categories
A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
Study of FT576 as Monotherapy and Combination with Daratumumab in Subjects with r/r MM
Protocol No
FATE-FT576-101-MM
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VAry
Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer (INNOVATE)
Protocol No
NRG-GU008-INNOVATE
Categories
Asciminib as Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission
Asciminib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase
Protocol No
HJKC3-0004
Categories